GlassScriptPhysician profile
Mazen Zaarour
NPI 1437599875
$10,880.14
in general payments reported to CMS, 2019-2025
62 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $448 · 2021: $542 · 2022: $2,564 · 2023: $2,457 · 2024: $2,073 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,218 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,217.75 |
| Education | $142.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $894.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $756.16 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $743.62 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Pfizer INC. | $730.16 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $701.75 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Genentech USA, INC. | $550.19 | 2019-2025 | Tecentriq, Venclexta, Phesgo |
| Celgene Corporation | $549.76 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $520.53 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $456.78 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $391.03 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Amgen INC. | $390.98 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Astellas Pharma US INC | $355.09 | 2020-2025 | Padcev, Xtandi, Vyloy |
| Regeneron Healthcare Solutions, INC. | $274.81 | 2022-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $243.24 | 2020-2025 | Enhertu, Datroway |
| Seagen INC. | $210.36 | 2020-2023 | Adcetris, Padcev, Tukysa |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Zaarour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.